Antibody Therapeutics and Blood Antibody Therapeutics Industry Research Report 2023

Antibody Therapeutics and Blood Antibody Therapeutics Industry Research Report 2023


Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.

Highlights

The global Antibody Therapeutics and Blood Antibody Therapeutics market is projected to reach US$ million by 2029 from an estimated US$ million in 2023, at a CAGR of % during 2024 and 2029.
The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Antibody Therapeutics and Blood Antibody Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Therapeutics and Blood Antibody Therapeutics.
The Antibody Therapeutics and Blood Antibody Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antibody Therapeutics and Blood Antibody Therapeutics market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Therapeutics and Blood Antibody Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights


In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche
Abbvie
Johnson & Johnson
Bristol-Myers Squibb
Novartis
Merck
Alexion Pharmaceuticals
Takeda
Amgen
Biogen
UCB
Eli Lilly and Company
AstraZeneca

Product Type Insights

Global markets are presented by Antibody Therapeutics and Blood Antibody Therapeutics type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Antibody Therapeutics and Blood Antibody Therapeutics are procured by the companies.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).
Antibody Therapeutics and Blood Antibody Therapeutics segment by Type

IgG1
IgG4
Others

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).
This report also outlines the market trends of each segment and consumer behaviors impacting the Antibody Therapeutics and Blood Antibody Therapeutics market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Antibody Therapeutics and Blood Antibody Therapeutics market.
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Application

Autoimmune
Tumor
Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Antibody Therapeutics and Blood Antibody Therapeutics market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Therapeutics and Blood Antibody Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Antibody Therapeutics and Blood Antibody Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Antibody Therapeutics and Blood Antibody Therapeutics industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Therapeutics and Blood Antibody Therapeutics.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody Therapeutics and Blood Antibody Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Frequently Asked Questions

What factors will challenge the Product Name market growth?
Which end-use segment will expand at the fastest CAGR in the Product Name market?
Which are the emerging players in the Product Name market?
How concentrated is the Product Name market?
Which factors are positively contributing to the Product Name market growth?
Which are the novel product innovations in the Product Name market?
Which product segment will emerge as the most lucrative in the Product Name market?
Which factors are increasing the competition in the Product Name market?
Which are the strategic measures taken by the Product Name industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Product Name market in the coming years?


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Antibody Therapeutics and Blood Antibody Therapeutics by Type
2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
1.2.2 IgG1
1.2.3 IgG4
1.2.4 Others
2.3 Antibody Therapeutics and Blood Antibody Therapeutics by Application
2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
2.3.2 Autoimmune
2.3.3 Tumor
2.3.4 Others
2.4 Assumptions and Limitations
3 Antibody Therapeutics and Blood Antibody Therapeutics Breakdown Data by Type
3.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Type (2018-2023)
3.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Type (2023-2028)
4 Antibody Therapeutics and Blood Antibody Therapeutics Breakdown Data by Application
4.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Application (2018-2023)
4.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Application (2018-2023)
5 Global Growth Trends
5.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Perspective (2018-2029)
5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Growth Trends by Region
5.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
5.2.2 Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Region (2018-2023)
5.2.3 Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Region (2024-2029)
5.3 Antibody Therapeutics and Blood Antibody Therapeutics Market Dynamics
5.3.1 Antibody Therapeutics and Blood Antibody Therapeutics Industry Trends
5.3.2 Antibody Therapeutics and Blood Antibody Therapeutics Market Drivers
5.3.3 Antibody Therapeutics and Blood Antibody Therapeutics Market Challenges
5.3.4 Antibody Therapeutics and Blood Antibody Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Antibody Therapeutics and Blood Antibody Therapeutics Players by Revenue
6.1.1 Global Top Antibody Therapeutics and Blood Antibody Therapeutics Players by Revenue (2018-2023)
6.1.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Players (2018-2023)
6.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Industry Players Ranking, 2021 VS 2022 VS 2023
6.3 Global Key Players of Antibody Therapeutics and Blood Antibody Therapeutics Head office and Area Served
6.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Players, Product Type & Application
6.5 Global Antibody Therapeutics and Blood Antibody Therapeutics Players, Date of Enter into This Industry
6.6 Global Antibody Therapeutics and Blood Antibody Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2018-2029)
7.2 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023)
7.4 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029)
7.5 United States
7.6 Canada
8 Europe
8.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2018-2029)
8.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
8.3 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023)
8.4 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2018-2029)
9.2 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023)
9.4 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
10 Latin America
10.1 Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2018-2029)
10.2 Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023)
10.4 Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029)
9.4 Mexico
9.5 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2018-2029)
11.2 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
11.3 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023)
11.4 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
12 Players Profiled
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.1.4 Roche Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.1.5 Roche Recent Development
11.2 Abbvie
11.2.1 Abbvie Company Detail
11.2.2 Abbvie Business Overview
11.2.3 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.2.4 Abbvie Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.2.5 Abbvie Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Detail
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.3.4 Johnson & Johnson Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.3.5 Johnson & Johnson Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.4.4 Bristol-Myers Squibb Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.5.4 Novartis Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.5.5 Novartis Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.6.4 Merck Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.6.5 Merck Recent Development
11.7 Alexion Pharmaceuticals
11.7.1 Alexion Pharmaceuticals Company Detail
11.7.2 Alexion Pharmaceuticals Business Overview
11.7.3 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.7.4 Alexion Pharmaceuticals Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.7.5 Alexion Pharmaceuticals Recent Development
11.8 Takeda
11.8.1 Takeda Company Detail
11.8.2 Takeda Business Overview
11.8.3 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.8.4 Takeda Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.8.5 Takeda Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.9.4 Amgen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.9.5 Amgen Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.10.4 Biogen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.10.5 Biogen Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.11.4 UCB Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.11.5 UCB Recent Development
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Detail
11.12.2 Eli Lilly and Company Business Overview
11.12.3 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.12.4 Eli Lilly and Company Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.12.5 Eli Lilly and Company Recent Development
11.13 AstraZeneca
11.13.1 AstraZeneca Company Detail
11.13.2 AstraZeneca Business Overview
11.13.3 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Introduction
11.13.4 AstraZeneca Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022)
11.13.5 AstraZeneca Recent Development
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US$ Million)
Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US$ Million)
Table 5. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 6. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Type (2018-2023)
Table 7. Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 8. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Type (2024-2029)
Table 9. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 10. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Application (2018-2023)
Table 11. Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 12. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Application (2024-2029)
Table 13. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 14. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 15. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Region (2018-2023)
Table 16. Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 17. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Region (2024-2029)
Table 18. Antibody Therapeutics and Blood Antibody Therapeutics Market Trends
Table 19. Antibody Therapeutics and Blood Antibody Therapeutics Market Drivers
Table 20. Antibody Therapeutics and Blood Antibody Therapeutics Market Challenges
Table 21. Antibody Therapeutics and Blood Antibody Therapeutics Market Restraints
Table 22. Global Top Antibody Therapeutics and Blood Antibody Therapeutics Manufacturers by Revenue (US$ Million) & (2018-2023)
Table 23. Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Manufacturers (2018-2023)
Table 24. Global Antibody Therapeutics and Blood Antibody Therapeutics Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
Table 25. Global Key Players of Antibody Therapeutics and Blood Antibody Therapeutics, Headquarters and Area Served
Table 26. Global Antibody Therapeutics and Blood Antibody Therapeutics Manufacturers, Product Type & Application
Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Antibody Therapeutics and Blood Antibody Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. North America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 33. Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 34. Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 35. Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 36. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 37. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 39. Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 40. Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 42. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 43. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 44. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2024-2029) & (US$ Million)
Table 45. Roche Company Detail
Table 46. Roche Business Overview
Table 47. Roche Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 48. Roche Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Roche Recent Development
Table 50. Abbvie Company Detail
Table 51. Abbvie Business Overview
Table 52. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 53. Abbvie Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Abbvie Recent Development
Table 55. Johnson & Johnson Company Detail
Table 56. Johnson & Johnson Business Overview
Table 57. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 58. Johnson & Johnson Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Johnson & Johnson Recent Development
Table 60. Bristol-Myers Squibb Company Detail
Table 61. Bristol-Myers Squibb Business Overview
Table 62. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 63. Bristol-Myers Squibb Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Bristol-Myers Squibb Recent Development
Table 65. Novartis Company Detail
Table 66. Novartis Business Overview
Table 67. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 68. Novartis Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Novartis Recent Development
Table 70. Merck Company Detail
Table 71. Merck Business Overview
Table 72. Merck Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 73. Merck Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Merck Recent Development
Table 75. Alexion Pharmaceuticals Company Detail
Table 76. Alexion Pharmaceuticals Business Overview
Table 77. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 78. Alexion Pharmaceuticals Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Alexion Pharmaceuticals Recent Development
Table 80. Takeda Company Detail
Table 81. Takeda Business Overview
Table 82. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 83. Takeda Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Takeda Recent Development
Table 85. Amgen Company Detail
Table 86. Amgen Business Overview
Table 87. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 88. Amgen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 89. Amgen Recent Development
Table 90. Biogen Company Detail
Table 91. Biogen Business Overview
Table 92. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product
Table 93. Biogen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Biogen Recent Development
Table 95. UCB Company Detail
Table 96. UCB Business Overview
Table 97. UCB Antibody Therapeutics and Blood Antibody TherapeuticsProduct
Table 98. UCB Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 99. UCB Recent Development
Table 100. Eli Lilly and Company Company Detail
Table 101. Eli Lilly and Company Business Overview
Table 102. Eli Lilly and Company Antibody Therapeutics and Blood Antibody TherapeuticsProduct
Table 103. Eli Lilly and Company Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 104. Eli Lilly and Company Recent Development
Table 105. AstraZeneca Company Detail
Table 106. AstraZeneca Business Overview
Table 107. AstraZeneca Antibody Therapeutics and Blood Antibody TherapeuticsProduct
Table 108. AstraZeneca Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2017-2022) & (US$ Million)
Table 109. AstraZeneca Recent Development
Table 110. Roche Company Information
Table 111. Roche Business Overview
Table 112. Roche Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 113. Roche Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 114. Roche Recent Development
Table 115. Abbvie Company Information
Table 116. Abbvie Business Overview
Table 117. Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 118. Abbvie Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 119. Abbvie Recent Development
Table 120. Johnson & Johnson Company Information
Table 121. Johnson & Johnson Business Overview
Table 122. Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 123. Johnson & Johnson Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 124. Johnson & Johnson Recent Development
Table 125. Bristol-Myers Squibb Company Information
Table 126. Bristol-Myers Squibb Business Overview
Table 127. Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 128. Bristol-Myers Squibb Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 129. Bristol-Myers Squibb Recent Development
Table 130. Novartis Company Information
Table 131. Novartis Business Overview
Table 132. Novartis Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 133. Novartis Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 134. Novartis Recent Development
Table 135. Merck Company Information
Table 136. Merck Business Overview
Table 137. Merck Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 138. Merck Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 139. Merck Recent Development
Table 140. Alexion Pharmaceuticals Company Information
Table 141. Alexion Pharmaceuticals Business Overview
Table 142. Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 143. Alexion Pharmaceuticals Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 144. Alexion Pharmaceuticals Recent Development
Table 145. Takeda Company Information
Table 146. Takeda Business Overview
Table 147. Takeda Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 148. Takeda Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 149. Takeda Recent Development
Table 150. Amgen Company Information
Table 151. Amgen Business Overview
Table 152. Amgen Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 153. Amgen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 154. Amgen Recent Development
Table 155. Biogen Company Information
Table 156. Biogen Business Overview
Table 157. Biogen Antibody Therapeutics and Blood Antibody Therapeutics Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 158. Biogen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 159. Biogen Recent Development
Table 160. UCB Company Information
Table 161. UCB Business Overview
Table 162. UCB Antibody Therapeutics and Blood Antibody TherapeuticsRevenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 163. UCB Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 164. UCB Recent Development
Table 165. Eli Lilly and Company Company Information
Table 166. Eli Lilly and Company Business Overview
Table 167. Eli Lilly and Company Antibody Therapeutics and Blood Antibody TherapeuticsRevenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 168. Eli Lilly and Company Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 169. Eli Lilly and Company Recent Development
Table 170. AstraZeneca Company Information
Table 171. AstraZeneca Business Overview
Table 172. AstraZeneca Antibody Therapeutics and Blood Antibody TherapeuticsRevenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million)
Table 173. AstraZeneca Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2018-2023) & (US$ Million) Portfolio
Table 174. AstraZeneca Recent Development
Table 175. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Antibody Therapeutics and Blood Antibody Therapeutics Product Picture
Figure 5. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 6. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Type: 2022 VS 2029
Figure 7. IgG1 Product Picture
Figure 8. IgG4 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Application (2023-2029) & (US$ Million)
Figure 11. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Application: 2022 VS 2029
Figure 12. Autoimmune Product Picture
Figure 13. Tumor Product Picture
Figure 14. Others Product Picture
Figure 15. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Region: 2022 VS 2029
Figure 18. Global Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Players in 2022
Figure 19. Global Antibody Therapeutics and Blood Antibody Therapeutics Players, Date of Enter into This Industry
Figure 20. Global Top 5 and 10 Antibody Therapeutics and Blood Antibody Therapeutics Players Market Share by Revenue in 2022
Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 22. North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. North America Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Country (2018-2029)
Figure 24. United States Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Country (2018-2029)
Figure 28. Germany Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. France Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. U.K. Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Italy Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Russia Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Nordic Countries Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Country (2018-2029)
Figure 36. China Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Japan Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. South Korea Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Southeast Asia Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. India Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Australia Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Latin America Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Country (2018-2029)
Figure 44. Mexico Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Brazil Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Share by Country (2018-2029)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings